Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TER
NCT03489629Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2018
- Primary completion
- Sep 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trimethoprim + sulfamethoxazole, minocycline, mupirocin, chlorhexidine in Staphylococcus aureus infection, sponsored by University of North Carolina at Chapel Hill. Started Apr 2018; status: completed.
02
Drugs
trimethoprim + sulfamethoxazoleminocyclinemupirocinchlorhexidine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03489629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489629.